nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.02.2007

Streptokinase—the drug of choice for thrombolytic therapy

verfasst von: Adinarayana Kunamneni, Thaer Taleb Abed Abdelghani, Poluri Ellaiah

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Thrombosis, the blockage of blood vessels with clots, can lead to acute myocardial infarction and ischemic stroke, both leading causes of death. Other than surgical interventions to remove or by pass the blockage, or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration of thrombolytic agents to dissolve the blood clot. This article describes a comprehensive review of streptokinase (SK). We discuss the biochemistry and molecular biology of SK, describing the mechanism of action, structures, confirmational properties, immunogenecity, chemical modification, and cloning and expression. The production and physico-chemical properties of this SK are also discussed. In this review, considering the properties and characteristics of SK that make it the drug of choice for thrombolytic therapy.

Collen D, Stump DC, Gold HK (1988) Thrombolytic therapy. Annu Rev Med 39:405–423PubMed

Bick RL (1985) Thrombolytic therapy. In: Bick RL (ed) Disorders of homeostasis and thrombosis, principles of clinical practice. Thieme Inc., New York

Collen D, Lijnen JR (1986) The fibrinolytic system in man. Crit Rev Hemat Oncol 4:249–301

Castellino FJ (1981) Recent advances in the chemistry of the fibrinolytic system. Chem Rev 81:431– 446

Collen D (1990) Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med 112:529–538PubMed

ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) The Lancet 339:753

Marder VJ (1993) Recombinant streptokinase—opportunity for an improved agent. Blood Coagul Fibrinolysis 4:1039–1040PubMed

Paoletti R, Sherry S (eds) (1977) Proceedings of the serono symposia. Thrombosis and Urokinase, vol. 9. Academic Publisher, London: p 257

Bick RL (1992) Disorders of thrombosis and hemostasis; Clinical and Laboratory Practice. ASCP Press, USA

10.

Wu KK, Thiagarajan P (1996) Role of endothelium in thrombosis and hemostasis. Annu Rev Med 47:315–331PubMed

11.

Bick RL (1982) Clinical relevance of anti-thrombin-III. Semin Thromb Hemost 8:276–287PubMed

12.

Castellino FJ (1984) Biochemistry of human-plasminogen. Semin Thromb Hemost 10:18–23PubMed

13.

Francis CW, Marder VJ (1994) Physiological regulation and pathologic disorders of fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Edwin W, Salzman B (eds) Hemostasis and thrombosis. J.B. Lippincott Company, Philadelphia, pp 1076–1103

14.

Summaria L, Robbins KL (1976) Isolation of human plasmid-derived functionally active light (B) chain capable of forming with streptokinase an equimolar light (B) chain-streptokinase complex with plasminogen activator activity. J Biol Chem 251:5810–5813PubMed

15.

Violand BN, Castellino FJ (1976) Mechanism of the urokinase-catalyzed activation of human plasminogen. J Biol Chem 251:3906–3912PubMed

16.

Wallen P, Wiman B (1972) Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochem Biophys Acta 257:122–134PubMed

17.

Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S (1972) Progress in chemical fibrinolysis and thrombolysis, vol. 3. Raven Press, New York, pp 191–209

18.

Pizzo SV, Schwartz ML Hill RL, McKee PA (1972) The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem 247:636–645PubMed

19.

Blomback B, Hessel B, Iwanaga S, Reuterby J, Blomback M (1972) Primary structure of human fibrinogen and fibrin. I. Cleavage of fibrinogen with cyanogen bromide. isolation and characterization of nh₂-terminal fragments of the α (“A”)chain. J Biol Chem 247:1496–1512PubMed

20.

Bachmann F (1987) Fibrinolysis. In: Verstaete M, Vermylen J, Lijnen R, Arnout J (eds) Thrombosis and haemostasis, Leuven Univ. Press, Leuven, Belgium, pp 227–235

21.

Collen D (1987) Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 33:77–86PubMed

22.

Akoi N, Harpel PC (1984) Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 10:24–41

23.

Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F (1984) Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 64:907–913PubMed

24.

Wiman B, Collen D (1978) On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 84:573–578PubMed

25.

Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL (1985) Cloning and expression of the gene for pro-urokinase in Escherichia coli. Biotechnol 3:923–929

26.

Wiman B, Collen D (1977) Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 78:19–26PubMed

27.

Wiman B (1980) On the reaction of plasmin or plasmin streptokinase complex with aprotinin or alpha-2-antitrypsin. Thromb Res 17:143–152PubMed

28.

Harpel PC (1973) Studies on human plasma α2-macroglobulin-enzyme interactions: evidence for proteolytic modification of the subunit chain structure. J Exp Med 138:508–521PubMed

29.

Harpel PC (1981) Alpha2-plasmin inhibitor and alpha2-macroglobulin–plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest 68:46–55PubMed

30.

Rajagopalan S, Gonias SL, Pizzo SV (1985) A non-antigenic covalent streptokinase polyethylene glycol complex with plasminogen activator function. J Clin Invest 75:413–419PubMedCrossRef

31.

Lack CH (1948) Staphylokinase: an activator of plasma protease. Nature 161:559–560PubMed

32.

Collen D, DeCock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM (1992) Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 6:232–242

33.

Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeid E, Pohl HD, Vandescheure S, Van De Werf F, Michael A, Collen D, Behnke D (1994) High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnol 12:185

34.

Okada K, Ueshima S, Fukao H, Matsuo O (2001) Analysis of complex formation between plasmin(ogen) and staphylokinase or streptokinase. Arch Biochem Biophys 393:339–341PubMed

35.

Smith RA, Dupe RJ, English PD, Green J (1981) Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nat 290:505–508

36.

Schluenring WD, Alagan A, Boidol W, Bringmann P, Petri T, Kratzschmar J, Haendler B, Langer G, Baldus B, Witt W, Donnar P (1992) Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Annals NY Acad Sci 667:395–403

37.

Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M (1990) Thrombolytic properties of staphylokinase. Blood 76:925–929PubMed

38.

Lijnen HR, Vanhoef B, DeCock F, Okada K, Ueshima S, Matsuo O, Collen D (1991) On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 266:11826–11832PubMed

39.

Sako T (1985) Overproduction of staphylokinase in Escherichia coli and its characterization. Eur J Biochem 149:557–563PubMed

40.

Behnke D, Gerlach D (1987) Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase, a bacterial plasminogen activator. Mol Gen Genet 210:528–534PubMed

41.

Nicolini FA, Nichols WW, Mehta JL, Saldeen TGP, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C (1992) Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue plasminogen activator. J Am Coll Cardiol. 20:228–235PubMed

42.

Adams DS, Griffin LA, Nachajko WR, Reddy VB, Wei CM (1991) A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 266:8476–8482PubMed

43.

Wu XC, Ye RQ, Duan YJ, Wong S-L (1998) Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. Appl Environ Microbiol 64:824–829PubMed

44.

Banerjee A, Chisti Y, Banerjee UC (2004) Streptokinase—a clinically useful thrombolytic agent. Biotechnol Adv 22:287–307PubMed

45.

Christensen LR (1945) Streptococcal fibrinolysis: a proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 28:363–383PubMed

46.

McClintock DK, Bell PH (1971) The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 43:694–702PubMed

47.

Summaria L, Arzadon L, Bernabe P, Robbins KC (1974) The interaction of streptokinase with human, cat, dog, and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen–streptokinase complexes. J Biol Chem 249:4760–4769PubMed

48.

Hummel BCW, Schor JM, Buck FF, Boggiano E, DeRenzo EC (1965) Quantitative enzymic assay of human plasminogen and plasmin with azocasein as substrate. Anal Biochem 11:532–547

49.

Reddy KNN, Markus G (1972) Mechanism of activation of human plasminogen by streptokinase presence of active center in streptokinase–plasminogen complex. J Biol Chem 247:1683–1691PubMed

50.

Schick LA, Castellino FJ (1973) Interaction of streptokinase and rabbit plasminogen. Biochemistry 12:4315–4321PubMed

51.

Kosow DP (1975) Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry 14:4459–4465PubMed

52.

Bajaj AP, Castellano FJ (1977) Activation of human plasminogen by equimolar levels of streptokinase. J Biol Chem 252:492–498PubMed

53.

Brockway WJ, Castellino FJ (1974) A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry 13:2063–2070PubMed

54.

Markus G, Werkheiser WC (1964) The interaction of streptokinase with plasminogen. i. functional properties of the activated enzyme. J Biol Chem 239:2637–2643PubMed

55.

Wulf RJ, Mertz ET (1969) Studies on plasminogen. Species specificity of streptokinase. Can J Biochem 47:927–931PubMedCrossRef

56.

McKee RJ, Hargrove CK, Smith AG, Mes H, Thompson A (1971) Precise calibration of a Ge(Li)-spectrometer using a digital to analog converter. Nuclear Instr Meth 92:421–432

57.

Sodetz JM, Brockway WJ, Castellino FJ (1972) Multiplicity of rabbit plasminogen. Physical characterization. Biochemistry 11:4451–4458PubMed

58.

Camiolo SM, Thorsen S, Astrup T (1971) Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 138:277–280PubMed

59.

Takada A, Ito T, Takada Y (1980) Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot. Thromb Haemost 43:20–23PubMed

60.

Violand BN, Byrne R, Castellino FJ (1978) The effect of alpha-, omega-amino acids on human plasminogen structure and activation. J Biol Chem 253:5395–5401PubMed

61.

Kim DM, Lee SJ, Kim IC, Kim ST, Byun SM (2000) Asp41–His48 region of streptokinase is important in binding to a substrate plasminogen. Thromb Res 99:93–98PubMed

62.

Kim IC, Kim JS, Lee SH, Byun SM (1996) C-terminal peptide of streptokinase, Met369–Pro373, is important in plasminogen activation. Biotechnol Mol Biol Int 40:939–945

63.

Kim DM, Lee SJ, Yoon SK, Byun SM (2002) Specificity role of the streptokinase C-terminal domain in plasminogen activation. Biochem Biophys Res Commun 290:585–588PubMed

64.

Zhai P, Wakeham N, Loy JA, Zhang XC (2003) Functional roles of streptokinase C-terminal flexible peptide in active site formation and substrate recognition in plasminogen activation. Biochemistry 42:114–120PubMed

65.

Wakeham N, Terzyan S, Zhai PZ, Loy JA, Tang J, Zhang XC (2002) Effects of deletion of streptokinase residues 48–59 on plasminogen activation. Protein Eng 15:753–761PubMed

66.

Wu DH, Shi GY, Chuang WJ, Hsu JM, Young KC, Chang CW, Wu HL (2001) Coiled coil region of streptokinase gamma-domain is essential for plasminogen activation. J Biol Chem 276:15025–15033PubMed

67.

Sazonova IY, Houng AK, Chowdhry SA, Reed GL (2000) Mechanism of action of a novel Streptococcus uberis plasminogen activator (SUPA). Circulation 102:489

68.

Boxrud PD, Bock PE (2000) Streptokinase binds preferentially to the extended conformation of plasminogen through lysine binding site and catalytic domain interactions. Biochemistry 39:13974–13981PubMed

69.

Boxrud PD, Verhamme IMA, Fay WP, Bock PE (2001) Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation. J Biol Chem 276:26084–26089PubMed

70.

Sundram V, Nanda JS, Rajagopal K, Dhar J, Chaudhary A, Sahni G (2003) Domain truncation studies reveal that the streptokinase–plasmin activator complex utilizes long range protein–protein interactions with macromolecular substrate to maximize catalytic turnover. J Biol Chem 278:30569–30577PubMed

71.

Shi GY, Chang BI, Chen SM, Wu DH, Wu HL (1994) Function of streptokinase fragments in plasminogen activation. Biochem J 304:235–241PubMed

72.

Young KC, Shi GY, Chang YF, Chang BI, Chang LC, Lai MD, Chuang WJ, Wu HL (1995) Interaction of streptokinase and plasminogen—studied with truncated streptokinase peptides. J Biol Chem 270:29601–29606PubMed

73.

McCoy HE, Broder CC, Lottenberg R (1991) Streptokinases produced by pathogenic group C Streptococci demonstrate species-specific plasminogen activation. J Infect Dis 164:515–521PubMed

74.

De Renzo EC, Siiteri PK, Hutchings BL, Bell PH (1967) Preparation and certain properties of highly purified streptokinase. J Biol Chem 242:533–542PubMed

75.

Taylor FB, Botts J (1968) Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry 7:232–242PubMed

76.

Jackson KW, Tang J (1982) Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry 21:6620–6625PubMed

77.

Malke H, Roe B, Ferretti J (1985) Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. Gene 34:357–362PubMed

78.

Huang TT, Malke H, Ferretti JJ (1989) Heterogeneity of the streptokinase gene in group A Streptococci. Infect Immun 57:502–506PubMed

79.

Malke H (1993) Polymorphism of the streptokinase gene—implications for the pathogenesis of poststreptococcal lomerulonephritis. Zentralbl Bakteriol 278:246–257PubMed

80.

Radek JT, Castellino FJ (1989) Conformational properties of streptokinase. J Biol Chem 264:9915–9922PubMed

81.

Fabian H, Naumann D, Misselwitz R, Ristau O, Gerlach D, Welfle H (1992) Secondary structure of streptokinase in aqueous solution—a Fourier transform infrared spectroscopic study. Biochemistry 31:6532–6538PubMed

82.

Misselwitz R Kraft R, Kostka S, Fabian H, Welfle K, Pfeil W, Welfle H, Gerlach D (1992) Limited proteolysis of streptokinase and properties of some fragments. Int J Biol Macromol 14:107–116

83.

Welfle K, Pfeil W, Misselwitz R, Welfle H, Gerlach D (1992) Conformational properties of streptokinase—differential scanning calorimetric investigations. Int J Biol Macromol 14:19–22PubMed

84.

Teuten AJ, Broadhurst RW, Smith RAG, Dobson CM (1993) Characterization of structural and folding properties of streptokinase by NMR-spectroscopy. Biochem J 290:313–319PubMed

85.

Conejero-Lara K, Parrado J, Azuaya AI, Smith RAG, Ponting CP, Dobson CM (1996) Thermal stability of the three domains of streptokinase studied by circular dichroism and nuclear magnetic resonance. Protein Sci 5:2583–2591PubMedCrossRef

86.

Parrado J, ConejeroLara F, Smith RAG, Marshall JM, Ponting CP, Dobson C (1996) The domain organization of streptokinase: nuclear magnetic resonance, circular dichroism, and functional characterization of proteolytic fragments. Protein Sci 5:693–704PubMedCrossRef

87.

Beldarrain A, Lopez-Lacomba JL, Kutyshenko VP, Serrano R, Cortijo M (2001) Multidomain structure of a recombinant streptokinase. A differential scanning calorimetry study. J Protein Chem 20:9–17PubMed

88.

Markus G, Evers JL, Hobika GH (1976) Activator activities of the transient forms of the human plasminogen·streptokinase complex during its proteolytic conversion to the stable activator complex. J Biol Chem 251:6495–504PubMed

89.

Siefring GE, Castellino FJ (1976) Interaction of streptokinase with plasminogen: isolation and characterization of a streptokinase degradation product. J Biol Chem 251:3913–3920PubMed

90.

Rodriguez P, Fuentes D, Munoz E, Rivero D, Orta D, Alburquerque S (1994) The streptokinase domain responsible for plasminogen binding. Fibrinolysis 8:276–285

91.

Reed GL, Lin LF, Parhami-Seren B, Kussie P (1995) Identification of a plasminogen binding region in streptokinase that is necessary of the creation a functional streptokinase–plasminogen activator complex. Biochemistry 34:10266–10271PubMed

92.

Nihalani D, Kumar R, Rajagopal K, Sahni G (1998) Role of the amino-terminal region of streptokinase in the generation of a fully functional plasminogen activator complex probed with synthetic peptides. Protein Sci 7:637–648PubMedCrossRef

93.

Wang X, Lin X, Loy JA, Tang J, Zhang XC (1998) Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 281:1662–1665PubMed

94.

Lizano S, Johnston KH (2005) Structural diversity of streptokinase and activation of human plasminogen. Infect Immun 73:4451–4453PubMed

95.

Azuaga AI, Dobson CM, Mateo PL, Conejero-Lara F (2002) Unfolding and aggregation during the thermal denaturation of streptokinase. Eur J Biochem 269:4121–4133PubMed

96.

Nihalani D, Sahni G (1995) Streptokinase contains two independent plasminogen-binding sites. Biochem Biophys Res Commun 217:1245–1254PubMed

97.

Young KC, Shi GY, Wu DH, Chang LC, Chang BI, Ou CP, Wu HL (1998) Plasminogen activation by streptokinase via a unique mechanism. J Biol Chem 273:3110–3116PubMed

98.

Reed GL, Liu L, Houng AK, Matsueda LH, Lizbeth H (1998) Mechanisms of fibrin independent and fibrin dependent plasminogen activation by streptokinase. Circulation 98:199

99.

Robinson BR, Liu L, Houng AK, Sazanova IY, Reed GL (2000) The streptokinase beta domain plays a critical role in activator complex formation and substrate docking. Circulation 102:490

100.

Sazonova IY, Robinson BR, Gladysheva IP, Castellino FJ, Reed GL (2004) α-Domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator. J Biol Chem 279:24994–25001PubMed

101.

Boxrud PD, Bock PE (2004) Conformational and proteolytic activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem 279:36642–36649PubMed

102.

Tillett WS, Garner RL (1933) Fibrinolytic activity of hemolytic streptococci. J Exp Med 58:485–502PubMed

103.

Ojalvo AG, Pozo L, Labarta V, Torrens I (1999a) Prevalence of circulating antibodies against a streptokinase C-terminal peptide in normal blood donors. Biochem Biophys Res Commun 263:454–459

104.

Kazmi KA, Iqbal MP, Rahbar A, Mehboobali N (2002) Anti-streptokinase titers and response to streptokinase treatment in Pakistani patients. Int J Cardiol 82:247–251PubMed

105.

Regnault V, Helft G, Wahl D, Czitrom D, Vuillemenot A, Papouin G, Roda L, Danchin N, Lecompte T (2003) Anti streptokinase platelet-activating antibodies are common and heterogeneous. J Thromb Hemost 1:1055–1061

106.

Ojalvo AG, Torrens I, Seralena A, de la Fuente J (1999) Recombinant streptokinase with reduced immunoreactivity. Thromb Hemost 77:815–817

107.

Torrens I, Ojalvo AG, Seralena A, de la Fuente J (1999a) Study of antigenic regions of streptokinase. Thromb Hemost 2288, Suppl. S

108.

Torrens I, Ojalvo AG, Seralena A, Hayes O, de la Fuente J (1999b) A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunol Lett 70:213–218

109.

Coffey JA, Jennings KR, Dalton H (2001) New antigenic regions of streptokinase are identified by affinity-directed mass spectrometry. Eur J Biochem 268:5215–5221PubMed

110.

Reed GL, Kussie P, Parhamiseren B (1993) A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. J Immunol 150:4407–4415PubMed

111.

Koide A, Suzuki S, Kobayashi S (1982) Preparation of polyethylene glycol-modified streptokinase with disappearance of binding ability towards antiserum and retention of activity. FEBS Lett 143:73–76PubMed

112.

Pautov VD, Anufrieva EV, Ananeva TD, Saveleva NV, Taratina TM, Krakovyak MG (1990) Structural dynamic and functional properties of native and modified streptokinase. Mol Biol 24:35–41

113.

Bean RR, Verhamme IM, Bock PE (2005) Role of the streptokinase α-domain in the interactions of streptokinase with plasminogen and plasmin. J Biol Chem 280:7504–7510PubMed

114.

Galler LI (2000) Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy. US patent 6087332

115.

Schotmuller H (1903) Die Artunterscheidung der fur den Menschen pathogenen Streptokokken durch Blutagar. Muench Med Wochenschr 1:849–909

116.

Lancefield RC (1933) A serological differentiation of human and other groups of hemolytic Streptococci. J Exp Med 57:571–595PubMed

117.

Feldman LJ (1974) Streptokinase manufacture. In German. German patent DE 2354019

118.

Hagenson MJ, Holden KA, Parker KA, Wood PJ, Cruze JA, Fuke M (1989) Expression of streptokinase in Pichia pastoris yeast. Enzyme Microb Technol 11:650–656

119.

Wong SL, Ye RQ, Nathoo S (1994) Engineering and production of streptokinase in Bacillus subtilis expression–secretion system. Appl Environ Microbiol 60:517–523PubMed

120.

Malke H, Ferretti JJ (1984) Streptokinase: cloning, expression and excretion by Escherichia coli. Proc Natl Acad Sci 81:3557–3561PubMed

121.

Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, Jacobs WR, Banerjee A, Cole S, Yuen KY, Clarridge III JE, Kreiswirth BN, Musser JM (1995) Rapid mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 119:131–138PubMed

122.

Malke H, Gerlach D, Kohler W, Ferretti JJ (1984) Expression of a streptokinase gene from Streptococcus equisimilis in Streptococcus sanguis. Mol Gen Genet 196:360–363PubMed

123.

Muller J, Reinert H, Malke H (1989) Streptokinase mutations relieving Escherichia coli K-12 (PRLA4) of detriments caused by the wild-type skc gene. J Bacteriol 171:2202–2208PubMed

124.

Estrada MP, Hernandez L, Perez A, Rodríguez P, Serrano R, Rubier AR (1992) High-level expression of streptokinase in Escherichia coli. Biotechnology 10:1138–1142PubMed

125.

Muller J, Malke H (1990) Duplication of the streptokinase gene in the chromosome of Streptococcus equisimilis H46A. FEMS Microbiol Lett 72:75–78

126.

Ko JH, Park DK, Kim IC, Lee SH, Byun SM (1995) High-level expression and secretion of streptokinase in Escherichia coli. Biotechnol Lett 17:1019–1024

127.

Pratap J, Rajamohan G, Dikshit KL (2000) Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation. Appl Microbiol Biotechnol 53:469–475PubMed

128.

Bernheimer AW, Gillman W, Hottle GA, Pappenheimer AM (1942) An improved medium for the cultivation of hemolytic streptococcus. J Bacteriol 43:495–498PubMed

129.

Rosenberger RF, Elsden SR (1960) The yields of Streptococcus faecalis grown in continuous culture. J Gen Microbiol 22:726–739PubMed

130.

Von Polnitz W, Sehwick HG, Bickhard JH (1962) (to Behringwerke. 31) SocietA Farmaceutici Italia, Indian Patent 73099, 22

131.

Davies HC, Karush F, Rudd JH (1965) Effect of amino acids on steady-state growth of a group A hemolytic streptococcus. J Bacteriol 89:421–427PubMed

132.

Holmström B (1968) Production of Streptokinase in Continuous Culture. Appl Microbiol 16:73–77PubMed

133.

Baewald G, Mayer G, Heikel R, Volzke KD, Roehlig R, Decker KL, Koehler W, Gerlach D (1975) Fermentative production of Streptococcus metabolites, especially streptokinase. German patent DD 111096

134.

Van de Rijn I, Kessler RE (1980) Growth characteristics of group A streptococci in a new chemically defined medium. Infect Immun 27:444–448PubMed

135.

Ozegowski JH, Gerlach D, Kohler W (1983) Influence of physical parameters on the production of streptococcal extracellular proteins in cultures with stabilized pH: 2. Temperature dependence of extracellular protein production. Zentralbl Bakteriol Microbiol Hyg 254:361–369

136.

Suh H, Kim KH, Kim SS, Han MH (1984) Culture conditions of Streptococcus sp. for streptokinase production. Sanop Misaengmul Hakhoechi 12:224–231

137.

Nemirovich-Danchenko MM, Alekseeva VN, Lebedeva VV, Shashkova NM, Feigel’man BI, Burovaya FI, Smirnova EM (1985) Streptokinase. In Russian. USSR patent SU 1147749

138.

Narciandi RE, Morbe FJ, Riesenberg D (1996) Maximizing the expression of recombinant kringle 1 (Streptokinase) synthesized in Escherichia coli. Influence of culture and induction conditions. Biotechnol Lett 18:1261–1266

139.

Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY

140.

Lee SH, Jeong ST, Kim IC, Byun SM (1997) Identification of the functional importance of valine-19 residue in streptokinase by N-terminal deletion and site directed mutagenesis. Biochem Mol Biol Int 41:199–207PubMed

141.

Mundada LV, Prorok M, DeFord ME, Figuera M, Castellino FJ, Fay WP (2003) Structure–function analysis of the streptokinase amino terminus (residues 1–59). J Biol Chem 278:24421–24427PubMed

142.

Yazdani SS, Mukherjee KJ (1998) Overexpression of streptokinase using a fed-batch strategy. Biotechnol Lett 20:923–927

143.

Yazdani SS, Mukherjee KJ (2002) Continuous culture studies on the stability and expression of recombinant streptokinase in Escherichia coli. Bioprocess Biosyst Eng 24:341–346

144.

Patnaik PR (2000) Principal component analysis for minimal model identification of a noise-affected fermentation: application to streptokinase. Biotechnol Lett 22:393

145.

Malke H, Steiner K, Gase K, Frank C (2000) Expression and regulation of the streptokinase gene. Methods 21:111–124PubMed

146.

Chisti Y (1998) Biosafety. In: G Subramanian (ed) Bioseparation and bioprocessing: a handbook, vol. 2, Wiley-VCH, New York, pp 379–415

147.

Pierard L, Bollen A (1990) Development of new thrombolytic agents using recombinant DNA technology. J Biotechnol 15:283–304PubMed

148.

Diwedi SK, Hiremath JS, Kerkar PG, Reddy Krishna N, Manjunath CN, Ramesh SS, Prabhavati S, Dhobe M, Singh Kavita, Bhusari P, Rao Raman (2005). Indigenous recombinant streptokinase Vs natural streptokinase in acute myocardial infarction patients: Phase III multicentric randomized double blind trial. Indian J Med Sci 59:200–207

149.

Goa KL, Henwood JM, Langley MS, Clissold SP (1990). Intravenous streptokinase: a reappraisal of its therapeutic use in acute myocardial infarction. Drugs 39:693–719PubMed

150.

Gruppo Italiano per lo Studio della Soppravvivenza nell’ Infart miocardico (GISSI-2) (1992) A factorial randomized trial of alteplase vs. streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 339:753–770CrossRef

151.

The TREMA Group investigators (1999) Multicenter, randomized, comparative study of recombinant vs. natural streptokinase in acute myocardial infarction. Thrombo Hemostat 82:1605–1609

152.

Honloser SH, Zabel M, Kasper W, Thomas M, Just H (1991) Assessment of coronary artery patency after thrombolytic therapy; accurate prediction utilising the combined analysis of three non-invasive markers. J Am Col Cardiol 18:44–49CrossRef

153.

Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica MR et al (2003) Early thrombolysis for the treatment of acute myocardial infarction: A systematic review and economic evaluation. Health Technol Assess 7:1–136PubMed

154.

Dundar Y, Hill R, Dickson R, Walley T (2003) Comparative efficacy of thrombolytics in acute myocardial infarction: A systematic review. QJM 96:103–113PubMed

Titel: Streptokinase—the drug of choice for thrombolytic therapy
verfasst von: Adinarayana Kunamneni
Thaer Taleb Abed Abdelghani
Poluri Ellaiah
Publikationsdatum: 01.02.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 1/2007
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-006-9011-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

The U.S. Thrombosis and Hemostasis Centers pilot sites program

Delay in invasive risk stratification of women with acute coronary syndrome is associated with worse outcomes

Does supervised exercise after deep venous thrombosis improve recanalization of occluded vein segments? A randomized study

Prevalence of Factor V 1691 G–A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis